Get the Stockscreener App
1.58
1.28%
0.02
Dare Bioscience Inc stock is traded at $1.58, with a volume of 43,654.
It is up +1.28% in the last 24 hours and down -5.95% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$1.56
Open:
$1.61
24h Volume:
43,654
Relative Volume:
0.30
Market Cap:
$22.72M
Revenue:
-
Net Income/Loss:
$-30.16M
P/E Ratio:
-4.6471
EPS:
-0.34
Net Cash Flow:
$-39.49M
1W Performance:
-5.39%
1M Performance:
-5.95%
6M Performance:
-26.51%
1Y Performance:
-48.20%
1-Day Range:
$1.56
$1.61
1-Week Range:
$1.56
$1.7046
52-Week Range:
$1.56
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.59 | 22.29M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dare Bioscience Inc Stock (DARE) Latest News
Daré Bioscience Updates Investor Presentation Under Regulation FD - TipRanks
Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K - Stock Titan
DARE Should I Buy - Intellectia AI
DARE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Daré Bioscience gets FDA clearance for HPV treatment trial By Investing.com - Investing.com India
Daré Bioscience gets FDA clearance for HPV treatment trial - Investing.com Australia
Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Bitget
Daré Bioscience Announces FDA Clearance of IND for Phase 2 - GlobeNewswire
New vaginal insert targets virus behind nearly all cervical cancers - Stock Titan
Dare Bioscience (DARE) CEO subscribes to Reg A units with warrants - Stock Titan
DARE SEC FilingsDare Bioscience Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dare Bioscience Launches Telehealth Consultations for Women's Arousal Cream - Intellectia AI
Dare Bioscience (DARE) Launches Telehealth for Topical Sildenafi - GuruFocus
First-of-its-kind arousal cream for women offers US-wide telehealth access - Stock Titan
Dare Bioscience Secures Strategic Autonomy with Key Asset Reversion - AD HOC NEWS
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com
Daré Bioscience Launches Regulation A Preferred Unit Offering - TipRanks
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Yahoo Finance
Dare Bioscience (NASDAQ:DARE) Share Price Passes Below 50-Day Moving Average – What’s Next? - Defense World
Daré Bioscience issues updated investor corporate presentation - MSN
Daré Bioscience Issues Updated Investor Corporate Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Dare Bioscience Earnings Notes - Trefis
Is Dare Bioscience Inc (DARE) a opportunity to investors? - uspostnews.com
Viagra for women rolling out in select states - NewsNation
A History of Outperforming Analyst Forecasts and Beating the Odds: Dare Bioscience Inc (DARE) - setenews.com
‘Viagra’ for women hits the shelves – 30 years after men got little blue pills - AOL.com
Sildenafil cream for female sexual arousal disorder available to prescribe in select states - Urology Times
DARE to PLAY sildenafil cream becomes commercially available for women in select states - Contemporary OB/GYN
Dare Bioscience (DARE) Launches Prescription for Women's Topical Arousal Cream - GuruFocus
Daré Bioscience Launches First-Ever Sildenafil Cream for Women, DARE to PLAY™ Sildenafil Cream, Enhancing Female Arousal and Sexual Health - Quiver Quantitative
Daré Bioscience (NASDAQ: DARE) starts 503B DARE to PLAY cream access in select states - Stock Titan
Viagra goes pink (finally!): First-of-its-kind cream promises to jump-start arousal in women - New York Post
Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits - Investing.com Canada
DARE: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 Targe - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer By Investing.com - Investing.com Canada
Dare Bioscience (DARE) Regains Ovaprene Rights from Bayer - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer - Investing.com
Dare Bioscience announces return of rights to Ovaprene phase 3 program ongoing positive interim data - marketscreener.com
Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data - TradingView — Track All Markets
Daré Bioscience (NASDAQ: DARE) regains Ovaprene rights after Phase 3 interim data - Stock Titan
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization - Sahm
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
[1-A] Dare Bioscience, Inc. SEC Filing - Stock Titan
Daré Bioscience receives $3.6 million grant payment for contraceptive work By Investing.com - Investing.com Nigeria
DARE Secures Additional $3.6 Million from Gates Foundation - GuruFocus
Daré Bioscience Receives $3.6 Million in Additional Grant Funding - The Manila Times
Daré Bioscience receives $3.6 million grant payment for contraceptive work - Investing.com
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):